Moreover, a high concentration of DTX was reported in SK-BR-3 breast cancer cell line on treatment with DTX-encapsulated dual-ligand hybrid NPs (IC50 value 0.98 ng/mL) than any other preparations due to the overexpression of Her2/neu. This evidence concerns the gene ERBB2 and breast cancer.